INVESTORS

Investor Overview

Corporate Profile

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.

Price

Change

Volume

Data Provided by Refinitiv. Minimum 15 minutes delayed.


IR Contact

Blaine Davis
Chief Financial Officer
Phone: 646-844-0337
Email: Blaine.Davis@protaratx.com

Scroll to Top